Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.

Donovan JL, Schroeder WS, Tran MT, Foster K, Forrest A, Lee TB, Gandhi PJ.

J Manag Care Pharm. 2007 Sep;13(7):598-606.

2.

Antiplatelet intervention in acute coronary syndrome.

Arora RR, Rai F.

Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Review.

PMID:
19092648
4.

[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].

Galli M, Maggioni AP, Vassanelli C, Tavazzi L.

Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian.

PMID:
10731377
5.

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.

Lincoff AM, Califf RM, Topol EJ.

J Am Coll Cardiol. 2000 Apr;35(5):1103-15. Review.

6.

Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.

Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology.

Circulation. 2007 May 15;115(19):2549-69. Review.

8.
9.

The role of eptifibatide in patients undergoing percutaneous coronary intervention.

Zeymer U.

Expert Opin Pharmacother. 2007 Jun;8(8):1147-54. Review.

PMID:
17516878
11.

Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.

Marsh JD.

Am J Health Syst Pharm. 2002 Nov 1;59(21 Suppl 7):S15-26. Review.

PMID:
12434711
12.
13.

Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.

Dyke CM.

Am Heart J. 1999 Oct;138(4 Pt 2):307-16. Review.

PMID:
10502236
14.

[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].

Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.

Herz. 2003 Aug;28(5):393-403. Review. German.

PMID:
12928738
15.

Bleeding risk and safety profile related to the use of eptifibatide: a current review.

Saab F, Ionescu C, Schweiger MJ.

Expert Opin Drug Saf. 2012 Mar;11(2):315-24. doi: 10.1517/14740338.2012.650164. Epub 2012 Jan 10. Review.

PMID:
22233272
16.

Eptifibatide overdose.

Parakh S, Naik N, Rohatgi N, Bhat U, Parakh K.

Int J Cardiol. 2009 Jan 24;131(3):430-2. Epub 2007 Nov 19. Review.

PMID:
18023892
17.

A systematic review of clinical pharmacist interventions in paediatric hospital patients.

Drovandi A, Robertson K, Tucker M, Robinson N, Perks S, Kairuz T.

Eur J Pediatr. 2018 Jun 19. doi: 10.1007/s00431-018-3187-x. [Epub ahead of print] Review.

PMID:
29915870
18.

Roles of Cardiology Pharmacists.

Yamaguchi H.

Yakugaku Zasshi. 2016;136(8):1121-3. doi: 10.1248/yakushi.15-00271-2. Review. Japanese.

19.

Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?

Doggrell SA.

Drugs Aging. 2010 Mar 1;27(3):239-54. doi: 10.2165/11532870-000000000-00000. Review.

PMID:
20210369
20.

Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.

Husted S.

Ther Clin Risk Manag. 2015 Feb 17;11:263-77. doi: 10.2147/TCRM.S75024. eCollection 2015. Review.

Supplemental Content

Support Center